| 2.9 0.2 (7.41%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.93 | 1-year : | 4.54 |
| Resists | First : | 3.37 | Second : | 3.89 |
| Pivot price | 2.99  |
|||
| Supports | First : | 2.52 | Second : | 2.1 |
| MAs | MA(5) : | 2.91 |
MA(20) : | 2.99 |
| MA(100) : | 2.44  |
MA(250) : | 2.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.1 |
D(3) : | 24.2 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 9.07 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ THAR ] has closed above bottom band by 25.9%. Bollinger Bands are 70.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.11 - 3.12 | 3.12 - 3.14 |
| Low: | 2.64 - 2.65 | 2.65 - 2.67 |
| Close: | 2.67 - 2.7 | 2.7 - 2.73 |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Thu, 23 Oct 2025
Tharimmune Decline Means Insider Profits Down To US$83k - simplywall.st
Wed, 22 Oct 2025
Will Tharimmune Inc. continue its uptrend - Portfolio Update Report & Low Risk Investment Opportunities - newser.com
Sat, 18 Oct 2025
Will Tharimmune Inc. stock remain a Wall Street favorite - Portfolio Gains Report & Weekly Hot Stock Watchlists - nchmf.gov.vn
Fri, 17 Oct 2025
Why Tharimmune Inc. stock could outperform in 2025 - Quarterly Earnings Summary & Smart Money Movement Alerts - nchmf.gov.vn
Mon, 06 Oct 2025
Tharimmune amends warrants to make 3.4 million shares immediately exercisable - Investing.com
Tue, 30 Sep 2025
Pleasing Signs As A Number Of Insiders Buy Tharimmune Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 37.9 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 355 (K) |
| Shares Short P.Month | 645 (K) |
| EPS | -6.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -140.4 % |
| Return on Equity (ttm) | -340.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 31.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|